Tag Archives: Diagnostics

RiboMed Biotechnologies gains CLIA certification for its new RiboMed Clinical Services Laboratory

April 19, 2011: Carlsbad, CA

RiboMed Biotechnologies announced today that it has received CLIA certification for its new RiboMed Clinical Services Laboratory to use its proprietary Abscription®- based DNA Methylation detection technologies for the development of new epigenetic diagnostics tests, particularly Companion Diagnostics (Theranostics). Theranostic tests can provide information as to a patient’s likelihood of responding to specific drug treatments, and RiboMed’s first theranostic tests will help oncologists make better decisions when treating patients with certain cancers. 

“Most people don’t realize what a small percentage of patients actually respond to most chemotherapies”, said RiboMed’s CEO, Dr. Michelle Hanna. “In many cases, only 20% of cancer patients improve with treatment, while the other 80% are not only resistant to the drug and do not respond, but they suffer even more due to the horrible side effects of most cancer drugs. Our new tests will provide physicians with badly needed information to help them make informed decisions about their patients’ treatment options. Patients who will not respond well to treatment should be given other options.”

The DNA methylation status of certain genes has been shown to predict the response to several types of drugs, and RiboMed’s proprietary tests for the detection of such methylation work well even with formalin-fixed paraffin embedded tissue (FFPE). These damaged patient samples can be very difficult to analyze with the most common DNA detection technology, which requires harsh chemical treatment of the patient DNA. RiboMed’s tests do not require chemical treatment and can be used on at least less patient sample than currently existing methods. “The ability to use smaller patient samples should allow more patients to be tested, even when there is very little or very damaged tissue available”, said Hanna. “These tests can save and improve lives.  Test for resistance first.”

About RiboMed Biotechnologies, Inc.

RiboMed Biotechnologies is a molecular diagnostic company, as well as a supplier of reagents and services to the translational medicine research community, with a focus on Epigenetic Diagnostics and Theranostics in Oncology. The Company develops and commercializes innovative technologies and products for disease screening, diagnostics, theranostics, post-treatment monitoring, and drug development utilizing its proprietary platform technology, Abscription®.

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our growth strategy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, and regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

RiboMed Receives $150,000 Epigenetics Research Contract From the National Cancer Institute

RiboMed Biotechnologies, Inc., a San Diego area biomarker discovery and diagnostics company, announced today the receipt of a $150,000 Phase I contract from the National Cancer Institute (NCI) to develop bisulfite-free, DNA methylation based diagnostic assays for prostate, bladder, kidney and testicular cancer.

 Tests will utilize RiboMed’s proprietary signal amplification technology, Abscription®. RiboMed has received four new U.S. patents related to Abscription® in the last year for disease- associated biomarker detection.

“This contract allows us to continue work that we started last year with NCI funding through its Innovative Molecular Analysis Technologies Program (IMAT),” said RiboMed CEO Michelle Hanna.

“RiboMed’s abscription-based detection tests are extremely sensitive and specific while still being affordable. They are ideally suited for non-invasive diagnostic and prognostic tests based on disease and drug associated biomarkers found in bodily fluids.”

About RiboMed Biotechnologies, Inc.

RiboMed Biotechnologies is performing leading edge research and development in the area of non-invasive tests and companion diagnostics for the early detection of for cancers and other diseases.

An Arizona corporation with research facilities in Carlsbad, California, RiboMed provides its customers, including leading Universities, Government Research Agencies and corporate partners with DNA Methylation Services, pre-packaged bi-sulfide free methylation test kits, and individual component compounds including a selection of Nucleotide Analogs and other products and supplies.RiboMed® products include:

· MethylMagnet® mCpG DNA Isolation Kits for researchers looking for an alternative to bisulfite conversion.

· MethylMagnet® mCpG Island Primer Kits for researchers who prefer a kitted solution with validated primers,

· MethylMagnet® Custom Assays for researchers that have a specific locus of interest

For more company information and a full product catalog, visit us on line at www.RiboMed.com.RiboMed®, Abscription®, and MethylMagnet® are registered trademarks of RiboMed Biotechnologies, Inc.


Michelle M. Hanna, PhD
CEO & Scientific Director
RiboMed Biotechnologies, Inc.
1989 Palomar Oaks Way, Suite B
Carlsbad, CA 92011

Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and RiboMed’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. RiboMed Biotechnologies, Inc. undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

RiboMed chosen to present at LifeScienceFest

FOLSOM, Calif., May 21, 2008 (BUSINESS WIRE) — Fifteen companies nationwide with innovations in medical devices, diagnostics and biotechnology have been chosen to present to investors and industry executives at TechCoire’s LifeScienceFest 2008 in Davis, Calif. The two-day conference will be held June 3-4 at the University of California, Davis’ Mondavi Center. Read the article Sacramento Business Journal